Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Common Equity (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Common Equity for 13 consecutive years, with $9.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 28.96% to $9.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.0 million, a 28.96% decrease, with the full-year FY2025 number at $9.0 million, down 28.96% from a year prior.
  • Common Equity was $9.0 million for Q4 2025 at Ekso Bionics Holdings, down from $9.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $41.0 million in Q1 2021 to a low of $9.0 million in Q4 2025.
  • A 5-year average of $22.0 million and a median of $16.5 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: soared 143300.0% in 2021, then crashed 50.45% in 2023.
  • Ekso Bionics Holdings' Common Equity stood at $37.2 million in 2021, then plummeted by 31.64% to $25.4 million in 2022, then plummeted by 50.45% to $12.6 million in 2023, then rose by 0.8% to $12.7 million in 2024, then fell by 28.96% to $9.0 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Common Equity are $9.0 million (Q4 2025), $9.7 million (Q3 2025), and $10.9 million (Q2 2025).